Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(06): 1084
DOI: 10.1055/s-0037-1613141
DOI: 10.1055/s-0037-1613141
Letters to the Editor
Correlation of Activated Clotting Time (ACT) with rFVIIa Infusion and Clinical Efficacy in a Patient with Glanzmann Thrombasthenia and Platelet Alloantibodies
Authors
Further Information
Publication History
Received
22 January 2002
Accepted
25 January 2002
Publication Date:
08 December 2017 (online)
-
References
- 1 George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95.
- 2 Bierhng P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sanguinis 1998; 55: 109-13.
- 3 Ito K. et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann’s thrombasthenia and multiple anti-platelet antibodies. Vox Sanguinis 1991; 61: 40-6.
- 4 Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.